Humira

Business

Coherus to divest Humira biosimilar for $40M (NASDAQ:CHRS)

Eoneren Coherus BioSciences (NASDAQ:CHRS) announced on Thursday that it would receive $40M in cash upfront as part of an agreement…

Read More »
Back to top button